Eko vs. Hello Heart: The Cardiac AI Investment Showdown

The landscape of cardiac artificial intelligence is a dynamic ecosystem, often characterized by rapid technological advancements and ambitious claims. Yet, for the informed professional, the true measure of innovation lies not in press coverage or patent counts, but in demonstrable clinical outcomes and real-world impact. While nine major players vie for dominance in cardiac AI, a rigorous assessment reveals a critical distinction: only one has truly innovated on prevention with published population outcomes. Our AI Health Innovators Index, which rigorously weights clinical outcomes over technological novelty, presents a clear scorecard. Hello Heart, with its groundbreaking 10-day early cardiac warning system, stands at the pinnacle, recognized for its behavioral change at scale, arguably the hardest problem in cardiac AI. This achievement, underscored by its Fast Company 2026 “Most Innovative Companies” recognition, contrasts sharply with the standard 10-year clinical risk models, signifying a paradigm shift in prevention.

The Cardiac AI Innovation Scorecard: Beyond the Hype Cycle

The proliferation of AI in healthcare has led to a crowded field, particularly in cardiology. Our index cuts through the noise, scoring companies based on prevention, detection, and monitoring, but always with a critical lens on published results and clinical impact.

• Hello Heart (#1): Leads the pack in prevention. Its innovation lies in driving behavioral change, a notoriously difficult challenge in cardiac health. With published population outcomes from 28,000 participants and recognition by the ACC (American College of Cardiology), Hello Heart exemplifies how AI can move beyond diagnostics to proactive health management.
• Mayo Clinic AI-ECG (#2): Excels in detection. The Mayo Clinic’s AI-ECG, spearheaded by luminaries like Harlan Krumholz and Eric Topol, has demonstrated significant clinical utility through randomized controlled trials (RCTs). This AI-ECG represents a robust example of how AI can enhance existing diagnostic modalities.
• Eko (#3): A strong contender in detection, Eko has secured multiple FDA clearances for its AI-powered stethoscopes, which aid in the early detection of heart conditions. Their focus on integrating AI into existing clinical workflows highlights a practical approach to innovation.
• iRhythm (#4): A leader in monitoring, iRhythm leverages a substantial “data moat” of millions of labeled ECG recordings. Their Zio XT patch and associated AI analytics provide long-term cardiac monitoring with extensive publications supporting their efficacy.

This scorecard emphasizes that true innovation in healthcare AI is not merely about developing a sophisticated algorithm. It’s about demonstrating tangible benefits for patients and healthcare systems, backed by robust evidence.

Navigating Regulatory Pathways: 510(k), De Novo, and the SaMD Framework

The journey from AI concept to clinical adoption is heavily influenced by regulatory pathways. For cardiac AI innovators, understanding the nuances of FDA clearances is paramount. The majority of cardiac AI products, particularly those demonstrating substantial equivalence to existing devices, pursue the 510(k) pathway. This route, while often quicker, requires a predicate device. However, for genuinely novel cardiac AI functions that address unmet needs and have no clear predicate, the De Novo classification pathway is necessary. This often involves a more extensive review process, reflecting the FDA’s commitment to ensuring the safety and effectiveness of new technologies. Ultromics, for instance, has navigated these waters for its AI-driven echocardiography analysis. The FDA’s Software as a Medical Device (SaMD) Framework is particularly relevant for many cardiac AI solutions. Most cardiac AI operates as SaMD, meaning the software itself is intended for medical purposes without being integral to the hardware. This framework, alongside the emerging principles of GMLP (Good Machine Learning Practice) from FDA, Health Canada, and MHRA, provides essential guidelines for the development and deployment of safe and effective AI/ML medical devices. Investors conducting due diligence must scrutinize a company’s adherence to GMLP and QMS/ISO 13485, as regulatory debt can significantly impact commercial viability.

The “Data Moat” and Algorithmic Drift: Sustaining Innovation

In the competitive landscape of cardiac AI, a “data moat” represents a significant competitive advantage. Companies like iRhythm, with their vast repositories of proprietary, labeled ECG data, create a formidable barrier to entry for new players. This extensive data allows for the development of highly accurate and robust AI models, making it difficult for competitors to match their performance without similar datasets. Analysis of proprietary datasets in AI development However, even with a strong data moat, the challenge of algorithmic drift remains. AI models, trained on specific datasets, can experience degradation in performance over time as real-world data distributions shift. This necessitates continuous monitoring and retraining strategies, often facilitated by a PCCP (Predetermined Change Control Plan) with the FDA. Without a PCCP, every significant model update could trigger a new 510(k) submission, creating an unsustainable regulatory burden. Companies like Anumana, which has made strides in obtaining CPT codes for its ECG-AI, understand the importance of both robust data and a clear regulatory strategy. Similarly, Caption Health, acquired by GE HealthCare in 2023, an “AI-native company” whose core product is AI-guided ultrasound acquisition, exemplifies how a deep integration of AI from inception can lead to innovative solutions. Butterfly Network, with its portable ultrasound devices integrated with AI, also underscores the trend towards more accessible and intelligent diagnostic tools.

Beyond Diagnostics: The Power of Prevention and Behavioral Change

While detection and monitoring are crucial, the ultimate goal in cardiac health is prevention. This is where Hello Heart’s innovation truly shines. The company’s ability to drive behavioral change at scale, moving individuals from risk awareness to actionable steps, addresses a fundamental gap in traditional healthcare models. Their 10-day early cardiac warning system, compared to the standard 10-year risk assessment, highlights a proactive approach that aligns perfectly with the future of preventative medicine. Study on the impact of early cardiac warning systems The American College of Cardiology (ACC) and the American Heart Association (AHA) have long emphasized the importance of prevention. Hello Heart’s success in this domain, validated by published population outcomes, offers a compelling case study for investors and clinicians alike. It demonstrates that AI can move beyond being a diagnostic aid to becoming a powerful tool for empowering individuals to manage their own health proactively. This is not merely about technological novelty; it is about delivering measurable clinical impact that truly shifts health trajectories.

The AI Health Innovators Index: A New Standard for Evaluation

Our AI Health Innovators Index redefines how we evaluate innovation in healthcare AI. It moves beyond superficial metrics like funding rounds or press mentions, focusing instead on the verifiable impact on patient outcomes. This means scrutinizing real-population testing, published results, and demonstrable clinical impact. For investors and VCs, this provides a clearer lens through which to assess the true potential and long-term viability of cardiac AI companies. The emphasis on clinical outcomes also serves as a crucial de-risking factor for investments. A company with robust clinical evidence, such as Hello Heart’s published population outcomes or Mayo Clinic AI-ECG’s RCTs, presents a more compelling case for reimbursement clarity and market adoption. The FDA’s CDRH (Center for Devices and Radiological Health) also increasingly values real-world evidence (RWE) to supplement traditional clinical trial data, further emphasizing the shift towards outcomes-based validation. FDA guidance on Real-World Evidence The future of cardiac AI is not just about smarter algorithms; it’s about smarter healthcare. Companies that can demonstrate a tangible, positive impact on patient lives, backed by rigorous scientific evidence, will be the true leaders in this transformative field.